Actuate Therapeutics (ACTU) Competitors $8.62 +0.07 (+0.82%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends ACTU vs. LENZ, ABUS, IMNM, EOLS, AUTL, ERAS, ORIC, VECT, TECX, and KURAShould you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include LENZ Therapeutics (LENZ), Arbutus Biopharma (ABUS), Immunome (IMNM), Evolus (EOLS), Autolus Therapeutics (AUTL), Erasca (ERAS), ORIC Pharmaceuticals (ORIC), VectivBio (VECT), Tectonic Therapeutic (TECX), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry. Actuate Therapeutics vs. LENZ Therapeutics Arbutus Biopharma Immunome Evolus Autolus Therapeutics Erasca ORIC Pharmaceuticals VectivBio Tectonic Therapeutic Kura Oncology Actuate Therapeutics (NASDAQ:ACTU) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability. Do insiders and institutionals believe in ACTU or LENZ? 54.3% of LENZ Therapeutics shares are owned by institutional investors. 38.4% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor ACTU or LENZ? LENZ Therapeutics received 10 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformActuate TherapeuticsN/AN/ALENZ TherapeuticsOutperform Votes10100.00% Underperform VotesNo Votes Does the media refer more to ACTU or LENZ? In the previous week, LENZ Therapeutics had 3 more articles in the media than Actuate Therapeutics. MarketBeat recorded 3 mentions for LENZ Therapeutics and 0 mentions for Actuate Therapeutics. LENZ Therapeutics' average media sentiment score of 0.93 beat Actuate Therapeutics' score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Actuate Therapeutics Neutral LENZ Therapeutics Positive Do analysts recommend ACTU or LENZ? LENZ Therapeutics has a consensus price target of $35.40, indicating a potential upside of 57.33%. Given LENZ Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00LENZ Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Is ACTU or LENZ more profitable? Actuate Therapeutics' return on equity of 0.00% beat LENZ Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A N/A LENZ Therapeutics N/A -58.48%-55.50% Which has stronger earnings & valuation, ACTU or LENZ? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$24.75MN/AN/ALENZ TherapeuticsN/AN/A-$124.65MN/AN/A SummaryLENZ Therapeutics beats Actuate Therapeutics on 9 of the 12 factors compared between the two stocks. Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACTU vs. The Competition Export to ExcelMetricActuate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$168.35M$6.21B$5.20B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E RatioN/A9.2687.2517.09Price / SalesN/A309.921,263.9177.22Price / CashN/A61.4443.7736.04Price / BookN/A6.055.314.79Net Income-$24.75M$154.90M$122.54M$224.99M7 Day Performance12.68%1.35%1.44%2.37%1 Month Performance27.33%0.41%2.51%4.40%1 Year PerformanceN/A3.08%25.32%20.10% Actuate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACTUActuate TherapeuticsN/A$8.62+0.8%N/AN/A$168.35MN/A0.0010Gap DownLENZLENZ Therapeutics2.1449 of 5 stars$22.61-2.6%$35.40+56.6%N/A$621.80MN/A0.00110Short Interest ↑Positive NewsABUSArbutus Biopharma2.755 of 5 stars$3.27-0.6%$5.50+68.2%+35.6%$619.64M$6.74M-7.6073Positive NewsIMNMImmunome1.8297 of 5 stars$9.83-7.3%$28.83+193.3%-26.0%$613.56M$10.13M-1.2140Short Interest ↑EOLSEvolus4.0075 of 5 stars$9.64-3.6%$23.00+138.6%-11.3%$610.41M$248.33M-10.59170News CoveragePositive NewsAUTLAutolus Therapeutics3.1922 of 5 stars$2.27-3.8%$10.40+358.1%-63.7%$604.03M$10.09M-1.88330Short Interest ↑Gap DownERASErasca3.0322 of 5 stars$2.11-11.0%$5.70+170.1%+8.8%$596.55MN/A-2.54126ORICORIC Pharmaceuticals3.7424 of 5 stars$8.23+3.4%$18.29+122.2%-4.4%$580.77MN/A-4.5780Gap UpVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030TECXTectonic Therapeutic2.9077 of 5 stars$38.40-4.4%$72.25+88.2%N/A$566.52MN/A-6.52120Positive NewsKURAKura Oncology4.3093 of 5 stars$7.11-2.9%$27.38+285.0%-50.6%$552.90MN/A-3.01130 Related Companies and Tools Related Companies LENZ Competitors ABUS Competitors IMNM Competitors EOLS Competitors AUTL Competitors ERAS Competitors ORIC Competitors VECT Competitors TECX Competitors KURA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACTU) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACTU Stock Alerts